Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results